Video
Author(s):
Douglas W. Sborov, MD, MS, discusses management strategies for bispecific antibody–related adverse effects in multiple myeloma.
Douglas W. Sborov, MD, MS, assistant professor, Division of Hematology and Hematologic Malignancies, Department of Internal Medicine, University of Utah School of Medicine; director, Multiple Myeloma Program and Division of Hematology Biorepository; member, Huntsman Cancer Institute (HCI) Experimental Therapeutics Program; physician leader, Multiple Myeloma/Bone Marrow Transplant arm, HCI Clinical Trials Office; and member, HCI Protocol Review and Monitoring Committee, Huntsman Translational Scholar, University of Utah Health, discusses management strategies for bispecific antibody–related adverse effects in multiple myeloma.
Low-grade cytokine release syndrome (CRS) is one of the main toxicities associated with bispecific antibodies, Sborov says. Early intervention with tocilizumab (Actemra) was met with hesitation initially because it was unknown whether it would negatively affect the efficacy of bispecific antibodies. However, the field now intervenes with tocilizumab even at the onset of grade 1 CRS, which improves the tolerability of the bispecific agent and does not decrease efficacy, Sborov explains.
However, given the COVID-19 pandemic, many institutions are experiencing a shortage with tocilizumab, which is pushing the field to evaluate other CRS management strategies, such as siltuximab (Sylvant) and anakinra (Kineret), Sborov says.
Cabazitaxel/Abiraterone Combination Prolongs PFS vs Abiraterone in mCRPC
Pembrolizumab Plus Sacituzumab Govitecan Shows Nonsignificant Trend Toward Improved PFS in HR+ Breast Cancer
Virtual and In-Person Delivery of Palliative Care Confers Equivalent QOL Benefit in Advanced Lung Cancer
Lymphadenectomy Fails to Boost Survival in Advanced Ovarian Cancer
2 Commerce Drive
Cranbury, NJ 08512